Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise
antiviral and immunomodulatory agents; however, no immunomodulator drug has been …
antiviral and immunomodulatory agents; however, no immunomodulator drug has been …
[HTML][HTML] Prognostic factors in hospitalized COVID-19 patients at the start of the pandemic in Colombia: a retrospective cohort study
JA Nuñez-Ramos, EF Illera, JLQ Barrios, HAM Arroyo… - Cureus, 2021 - ncbi.nlm.nih.gov
Objectives To determine prognostic factors in hospitalized COVID-19 patients and to
evaluate the impact of tocilizumab use in patients with hyperinflammatory syndrome and …
evaluate the impact of tocilizumab use in patients with hyperinflammatory syndrome and …
Tocilizumab for the treatment of severe coronavirus disease 2019
Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …
Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19
S Douedi, M Chaudhri, J Miskoff - Annals of Thoracic Medicine, 2020 - journals.lww.com
Abstract Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia
and acute respiratory distress syndrome which may lead to death. Several treatments have …
and acute respiratory distress syndrome which may lead to death. Several treatments have …
[HTML][HTML] Appropriate use of tocilizumab in COVID-19 infection
Objective This study aimed to describe the effectiveness and optimum use of tocilizumab
(TCZ) treatment by the support of clinical, laboratory and radiologic observations. Methods …
(TCZ) treatment by the support of clinical, laboratory and radiologic observations. Methods …
Tocilizumab use in patients with moderate to severe COVID‐19: a retrospective cohort study
What is known and objective The coronavirus disease 2019 (COVID‐19) associated
cytokine activation can lead to a rapid progression into respiratory failure, shock and …
cytokine activation can lead to a rapid progression into respiratory failure, shock and …
[HTML][HTML] Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
MA Kaminski, S Sunny, K Balabayova, A Kaur… - International Journal of …, 2020 - Elsevier
Background The release of pro-inflammatory cytokines, resulting in cytokine storm
syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This …
syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This …
Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID‐19 pneumonia patients
B Borku Uysal, H Ikitimur, S Yavuzer… - Journal of medical …, 2020 - Wiley Online Library
To recognize the period of exaggerated cytokine response in patients with coronavirus
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …
Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial
Background The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms
to severe complications, including acute respiratory distress syndrome. In this syndrome …
to severe complications, including acute respiratory distress syndrome. In this syndrome …
Tocilizumab improves the prognosis of COVID-19 in patients with high IL-6
R Flisiak, J Jaroszewicz, M Rogalska… - Journal of Clinical …, 2021 - mdpi.com
Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19)
includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab …
includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab …